30.04

1.11% -0.595

Akero Therapeutics Inc (AKRO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AKRO Giù? Forum Previsione

Precedente Chiudi:

$30.64

Aprire:

$30.88

Volume 24 ore:

18,948

Relative Volume:

0.04

Capitalizzazione di mercato:

$2.14B

Reddito:

Utile/perdita netta:

$-179.27M

Rapporto P/E:

-11.73

EPS:

-2.56

Flusso di cassa netto:

$-155.88M

1 W Prestazione:

+1.80%

1M Prestazione:

-1.96%

6M Prestazione:

+49.68%

1 anno Prestazione:

+88.52%

Intervallo 1D:

$30.00

$30.88

Intervallo di 1 settimana:

$27.05

$31.60

Portata 52W:

$15.32

$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Nome

Akero Therapeutics Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

650-487-6488

Indirizzo

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Dipendente

Cinguettio

@akerotx

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

AKRO's Discussions on Twitter

Confronta AKRO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AKRO	30.00	2.14B	0	-179.27M	-155.88M	-2.56
VRTX	445.48	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	736.17	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	584.39	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.28	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.25	24.49B	3.30B	-501.07M	1.03B	11.54

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-04-22	Ripresa	BofA Securities	Neutral
2023-09-19	Iniziato	Cantor Fitzgerald	Overweight
2023-08-28	Iniziato	UBS	Buy
2023-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-09-14	Aggiornamento	Evercore ISI	In-line → Outperform
2021-10-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-10	Iniziato	BofA Securities	Buy
2021-02-26	Iniziato	Guggenheim	Buy
2020-09-10	Iniziato	Morgan Stanley	Overweight
2020-07-20	Reiterato	H.C. Wainwright	Buy
2020-07-07	Iniziato	Chardan Capital Markets	Buy
2020-07-01	Reiterato	H.C. Wainwright	Buy
2020-03-02	Iniziato	H.C. Wainwright	Buy
2020-02-10	Iniziato	Canaccord Genuity	Buy
2019-07-15	Iniziato	Evercore ISI	Outperform
2019-07-15	Iniziato	JP Morgan	Overweight
2019-07-15	Iniziato	Jefferies	Buy
2019-07-15	Iniziato	ROTH Capital	Buy

Mostra tutto

Akero Therapeutics Inc Borsa (AKRO) Ultime notizie

06:04 AM

How To Trade (AKRO) - Stock Traders Daily

06:04 AM

Nov 20, 2024

NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors - Scrip

Nov 20, 2024

Nov 19, 2024

Akero Therapeutics' chief development officer sells $251,274 in stock - Investing.com

Nov 19, 2024

Citigroup Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN

Nov 19, 2024

Nov 18, 2024

Inventiva Getting Back On Track In NASH Development - Citeline News & Insights

Nov 18, 2024

Akero a new buy at Citi on liver disease asset - Seeking Alpha

Nov 18, 2024

HC Wainwright Reaffirms "Buy" Rating for Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

Nov 18, 2024

Citigroup Begins Coverage on Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

Nov 18, 2024

Citi bullish on Akero stock as efruxifermin targets MASH market leadership - Investing.com Canada

Nov 18, 2024

Nov 15, 2024

Akero Therapeutics (NASDAQ:AKRO) Shares Down 6.4%What's Next? - MarketBeat

Nov 15, 2024

Akero reports positive EFX trial results for liver disease By Investing.com - Investing.com Canada

Nov 15, 2024

Akero reports positive EFX trial results for liver disease - Investing.com

Nov 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Boosted by Simplify Asset Management Inc. - MarketBeat

Nov 15, 2024

Akero Therapeutics to Showcase New Analyses of Phase 2b - GlobeNewswire

Nov 15, 2024

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024 - Marketscreener.com

Nov 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Decline in Short Interest - MarketBeat

Nov 15, 2024

Janus Henderson Group PLC's Strategic Acquisition of Akero Thera - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

What is HC Wainwright's Estimate for AKRO FY2024 Earnings? - MarketBeat

Nov 14, 2024

RTW INVESTMENTS, LP Expands Stake in Akero Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024

Akero Therapeutics to Present at Jefferies London Healthcare Conference | AKRO Stock News - StockTitan

Nov 13, 2024

ALKEON CAPITAL MANAGEMENT LLC Reduces Stake in Akero Therapeutics Inc - GuruFocus.com

Nov 13, 2024

FY2028 EPS Forecast for Akero Therapeutics Raised by Analyst - MarketBeat

Nov 13, 2024

Akero Therapeutics (NASDAQ:AKRO) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 13, 2024

Nov 12, 2024

Akero Therapeutics Advances in MASH Treatment Trials - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateAkero Therapeutics, Inc. made significant strides in the third quarter of 2024, announcing the dosing of the first patient in the Phase 3 SYNCHRONY Outcomes study of i - Defense World

Nov 11, 2024

Nov 10, 2024

(AKRO) Trading Advice - Stock Traders Daily

Nov 10, 2024

Nov 09, 2024

Akero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Misses Estimates By $0.15 EPS - MarketBeat

Nov 09, 2024

Nov 08, 2024

Akero Therapeutics executive sells $351,890 in stock - Investing.com

Nov 08, 2024

Akero Therapeutics executive sells $351,890 in stock By Investing.com - Investing.com Australia

Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition of Akero Therapeutics Shares - GuruFocus.com

Nov 08, 2024